Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy

Launched by DR. TABASSUM WADASADAWALA · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the best way to treat patients with stage IIB-III invasive breast cancer after surgery. Specifically, researchers want to find out if giving chemotherapy and radiation therapy at the same time (concurrent treatment) is better than giving them one after the other (sequential treatment). They will look at how these different treatment schedules affect patients’ chances of staying cancer-free, their quality of life, any side effects they may experience (like swelling in the arms), and the costs of treatment.

To participate, you need to be an adult over 18 years old with a confirmed diagnosis of invasive breast cancer that is either stage IIB or III. You should also be planned for both chemotherapy and radiation therapy after your surgery. If you join the trial, you will receive standard chemotherapy along with radiation therapy for three to four weeks and have follow-up visits every six months for up to five years to monitor your health and any potential side effects. This study is currently recruiting participants and welcomes individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically confirmed invasive breast cancer
• • 2. Stage IIB-III invasive breast cancer (AJCC 8th edition)
• • 3. Patients planned for adjuvant chemotherapy and adjuvant radiotherapy
• • 4. Patients fit to receive adjuvant chemotherapy and radiotherapy
• • 5. Age \> 18 years
• Exclusion Criteria:
• • 1. Hypersensitivity to taxanes
• • 2. Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
• • 3. Unable or unwilling for regular follow up
• • 4. Bilateral tumour needed RT to both sides
• • 5. Patients planned for RT to oligometastatic sites
• • 6. Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and/or lungs (Exceeding the protocol specific mandatory dose constraints).
• • 7. Pregnant patient